Back to journals
Academic Journal

Journal of Clinical Pharmacology

5 Papers Indexed in Blossom

Data updated

Research Footprint

Journal of Clinical Pharmacology has 5 tracked papers indexed in Blossom (2014–2021) from 27 authors, most often covering Ibogaine, MDMA and Mescaline, across Depressive Disorders, Safety & Risk Management and Medicinal Chemistry & Drug Development.

Published Papers

Paywallmeta

MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: a systematic review with meta-analysis

This systematic review (2021) entails a meta-analysis of the current literature on MDMA-assisted therapy for the treatment of PTSD. It was found that MDMA significantly reduced CAPS scores and is generally safe and well tolerated although side effects such as headache and nausea are commonly reported.

Published
Journal
Journal of Clinical Pharmacology
Authors
Smith, K. W., Sicignano, D. J., Hernandez, A. V., White, M.
Paywallindividual

Ketamine for Refractory Chronic Migraine: an Observational Pilot Study and Metabolite Analysis

In this prospective observational pilot of six patients with refractory chronic migraine, both lidocaine and (R,S)-ketamine infusions produced short-term pain relief but pain had returned to baseline by follow-up, with ketamine giving a slightly larger yet clinically minimal greater reduction. Metabolite analysis showed (2R,6R)-hydroxynorketamine was the predominant ketamine metabolite during most of the infusion.

Published
Journal
Journal of Clinical Pharmacology
Authors
Schwenk, E. S., Torjman, M. C., Moaddel, R., Lovett, J., Katz, D., Denk, W., Lauritsen, C., Do, Silberstein, S. D., Wainer, I. W.
Paywallindividual

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers

This open-label study (n=21) investigated the pharmacokinetics of a single dose of ibogaine (20mg) in response to inhibiting its metabolism via pretreatment with the antidepressant paroxetine in a placebo-controlled manner. Results indicate that the dose was safe and well-tolerated in all subjects, although paroxetine greatly increased the half-life of ibogaine to detectable levels at 72 hours post-infusion.

Published
Journal
Journal of Clinical Pharmacology
Authors
Glue, P., Lenagh-Glue, Z., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Hung, C. T.
Paywallindividual

Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability

This ascending single-dose, placebo-controlled, randomised, double-blind, parallel-group study (n=36) investigated the safety and pharmacokinetic profile of orally ingested noribogaine (3, 10, 30, or 60mg), and found that it was rapidly absorbed and slowly eliminated, and generally safe and well-tolerated in healthy male volunteers.

Published
Journal
Journal of Clinical Pharmacology
Authors
Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., Friedhoff, L., Buckland, H.
Paywallmeta

How MDMAs Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

This review links MDMA’s combined amphetamine‑ and mescaline‑like pharmacology and pharmacokinetics — including enhanced release of serotonin, cortisol, oxytocin and antidiuretic hormone — to both its sought‑after stimulant, empathogenic and psychedelic effects and a spectrum of serious harms (hepatic injury, rhabdomyolysis, serotonin syndrome, cardiovascular events, prolonged depression and death). It also highlights how rave environmental factors (heat, exertion, loud music) amplify both desired effects and risks, arguing that this integrated knowledge is essential for education, harm reduction and clinical management.

Published
Journal
Journal of Clinical Pharmacology
Authors
White, C. M.

Quick Facts

Papers Indexed
5
h-Index
133
Open Access
No
Publisher
Wiley
Country
United States
Website
Visit